Dr. Georges has served as chief technology officer for Altimmune since March 2015. He has nearly two decades of experience in product formulation and manufacturing, preclinical and early-stage clinical development, with a focus on T cell and peptide-based vaccines. Prior to joining Altimmune, Dr. Georges co-founded Immune Targeting Systems (ITS) Limited and served as the chief technology officer from 2004 until its acquisition by Altimmune in March 2015. Prior to ITS, Dr. Georges served as the of head of immunology at SEDAC-Therapeutics from 1999 until 2003. He received his Ph.D. in Molecular Immunology from the Pasteur Institute. Dr. Georges has co-authored 20 publications and is the co-inventor of 13 patent families.